<?xml version='1.0' encoding='utf-8'?>
<document id="28674244"><sentence text="Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline."><entity charOffset="79-90" id="DDI-PubMed.28674244.s1.e0" text="Terbinafine" /><entity charOffset="95-108" id="DDI-PubMed.28674244.s1.e1" text="Amitriptyline" /><entity charOffset="112-125" id="DDI-PubMed.28674244.s1.e2" text="Nortriptyline" /><pair ddi="false" e1="DDI-PubMed.28674244.s1.e0" e2="DDI-PubMed.28674244.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28674244.s1.e0" e2="DDI-PubMed.28674244.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s1.e0" e2="DDI-PubMed.28674244.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s1.e1" e2="DDI-PubMed.28674244.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s1.e1" e2="DDI-PubMed.28674244.s1.e2" /></sentence><sentence text="The purpose of the study was to quantitatively estimate and predict drug interactions between terbinafine and tricyclic antidepressants (TCAs), amitriptyline or nortriptyline, based on in vitro studies"><entity charOffset="94-105" id="DDI-PubMed.28674244.s2.e0" text="terbinafine" /><entity charOffset="110-119" id="DDI-PubMed.28674244.s2.e1" text="tricyclic" /><entity charOffset="144-157" id="DDI-PubMed.28674244.s2.e2" text="amitriptyline" /><entity charOffset="161-174" id="DDI-PubMed.28674244.s2.e3" text="nortriptyline" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e0" e2="DDI-PubMed.28674244.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e0" e2="DDI-PubMed.28674244.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e0" e2="DDI-PubMed.28674244.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e0" e2="DDI-PubMed.28674244.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e1" e2="DDI-PubMed.28674244.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e1" e2="DDI-PubMed.28674244.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e1" e2="DDI-PubMed.28674244.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e2" e2="DDI-PubMed.28674244.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s2.e2" e2="DDI-PubMed.28674244.s2.e3" /></sentence><sentence text=" Inhibition of TCA-metabolizing activity by terbinafine was investigated using human liver microsomes"><entity charOffset="44-55" id="DDI-PubMed.28674244.s3.e0" text="terbinafine" /></sentence><sentence text=" Based on the unbound Ki values obtained in vitro and reported pharmacokinetic parameters, a pharmacokinetic model of drug interaction was fitted to the reported plasma concentration profiles of TCAs administered concomitantly with terbinafine to obtain the drug-drug interaction parameters"><entity charOffset="232-243" id="DDI-PubMed.28674244.s4.e0" text="terbinafine" /></sentence><sentence text=" Then, the model was used to predict nortriptyline plasma concentration with concomitant administration of terbinafine and changes of area under the curve (AUC) of nortriptyline after cessation of terbinafine"><entity charOffset="37-50" id="DDI-PubMed.28674244.s5.e0" text="nortriptyline" /><entity charOffset="107-118" id="DDI-PubMed.28674244.s5.e1" text="terbinafine" /><entity charOffset="164-177" id="DDI-PubMed.28674244.s5.e2" text="nortriptyline" /><entity charOffset="197-208" id="DDI-PubMed.28674244.s5.e3" text="terbinafine" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e0" e2="DDI-PubMed.28674244.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e0" e2="DDI-PubMed.28674244.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e0" e2="DDI-PubMed.28674244.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e0" e2="DDI-PubMed.28674244.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e1" e2="DDI-PubMed.28674244.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e1" e2="DDI-PubMed.28674244.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e1" e2="DDI-PubMed.28674244.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e2" e2="DDI-PubMed.28674244.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s5.e2" e2="DDI-PubMed.28674244.s5.e3" /></sentence><sentence text=" The CYP2D6 inhibitory potency of terbinafine was unaffected by preincubation, so the inhibition seems to be reversible"><entity charOffset="34-45" id="DDI-PubMed.28674244.s6.e0" text="terbinafine" /></sentence><sentence text=" Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13"><entity charOffset="1-12" id="DDI-PubMed.28674244.s7.e0" text="Terbinafine" /><entity charOffset="37-50" id="DDI-PubMed.28674244.s7.e1" text="amitriptyline" /><entity charOffset="54-67" id="DDI-PubMed.28674244.s7.e2" text="nortriptyline" /><pair ddi="false" e1="DDI-PubMed.28674244.s7.e0" e2="DDI-PubMed.28674244.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28674244.s7.e0" e2="DDI-PubMed.28674244.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s7.e0" e2="DDI-PubMed.28674244.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s7.e1" e2="DDI-PubMed.28674244.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s7.e1" e2="DDI-PubMed.28674244.s7.e2" /></sentence><sentence text="7 and 12" /><sentence text="4â€‰nM, respectively" /><sentence text=" Observed plasma concentrations of TCAs administered concomitantly with terbinafine were successfully simulated with the drug interaction model using the in vitro parameters"><entity charOffset="72-83" id="DDI-PubMed.28674244.s10.e0" text="terbinafine" /></sentence><sentence text=" Model-predicted nortriptyline plasma concentration after concomitant nortriptylene/terbinafine administration for two weeks exceeded the toxic level, and drug interaction was predicted to be prolonged; the AUC of nortriptyline was predicted to be increased by 2"><entity charOffset="17-30" id="DDI-PubMed.28674244.s11.e0" text="nortriptyline" /><entity charOffset="70-83" id="DDI-PubMed.28674244.s11.e1" text="nortriptylene" /><entity charOffset="84-95" id="DDI-PubMed.28674244.s11.e2" text="terbinafine" /><entity charOffset="214-227" id="DDI-PubMed.28674244.s11.e3" text="nortriptyline" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e0" e2="DDI-PubMed.28674244.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e0" e2="DDI-PubMed.28674244.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e0" e2="DDI-PubMed.28674244.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e0" e2="DDI-PubMed.28674244.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e1" e2="DDI-PubMed.28674244.s11.e1" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e1" e2="DDI-PubMed.28674244.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e1" e2="DDI-PubMed.28674244.s11.e3" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e2" e2="DDI-PubMed.28674244.s11.e2" /><pair ddi="false" e1="DDI-PubMed.28674244.s11.e2" e2="DDI-PubMed.28674244.s11.e3" /></sentence><sentence text="5- or 2" /><sentence text="0- and 1" /><sentence text="5-fold at 0, 3 and 6 months after cessation of terbinafine, respectively"><entity charOffset="47-58" id="DDI-PubMed.28674244.s14.e0" text="terbinafine" /></sentence><sentence text=" The developed model enables us to quantitatively predict the prolonged drug interaction between terbinafine and TCAs"><entity charOffset="97-108" id="DDI-PubMed.28674244.s15.e0" text="terbinafine" /></sentence><sentence text=" The model should be helpful for clinical management of terbinafine-CYP2D6 substrate drug interactions, which are difficult to predict due to their time-dependency" /><sentence text="" /></document>